Dopamine agonist monotherapy in Parkinson's disease

@article{Clarke2002DopamineAM,
  title={Dopamine agonist monotherapy in Parkinson's disease},
  author={Ce Clarke and Mark Guttman},
  journal={The Lancet},
  year={2002},
  volume={360},
  pages={1767-1769}
}
Dopamine agonists in Parkinson’s disease
TLDR
Dopamine agonists (DAs) have been shown to be about as effective as LD in symptomatic treatment of mild-to-moderate PD and there is a lower tendency to develop motor fluctuations and dyskinesias with DA treatment than after initiation of therapy with LD.
Existing dopaminergic therapies for Parkinson's disease
TLDR
A brief review on different dopamine receptor agonists has been presented and indirect dopaminergic agents, such as selective monoamine oxidase-B inhibitors and catechol-O-methyltransferase inhibitors, have also been included in the description.
Management of Parkinson Disease
TLDR
It is in the setting of early Parkinson disease that ropinirole may see greatest expansion of its overall role in disease management programs, and as monotherapy or in combination with low-dose levodopa in early disease, it is generally more effective than bromocriptine and moreeffective than placebo.
Existing dopaminergic therapies for Parkinson’s disease
TLDR
A brief review on different dopamine receptor agonists has been presented and indirect dopaminergic agents, such as selective monoamine oxidase-B inhibitors and catechol-O-methyltransferase inhibitors, have also been included in the description.
Pathological gambling and dopamine agonists: A phenotype?
  • R. Pinder
  • Psychology
    Neuropsychiatric disease and treatment
  • 2007
TLDR
The first cases of pathological gambling in 3 patients with RLS under treatment with dopamine agonists mainly pramipexole have been reported, and a possible ‘phenotype’ based on the four As: anxiety, anger, age, and agonists is proposed.
Advances in dopamine receptor agonists for the treatment of Parkinson’s disease
TLDR
This review investigates recent updates on DA therapy, the role of these compounds in controlling non-motor symptoms (NMS) as well as new formulations under clinical evaluation and newly emerged post-marketing safety considerations.
Parkinson's disease: emerging pharmacotherapy
TLDR
Current therapies and possible future developments that are hoped will contribute to sustaining quality of life in patients suffering from Parkinson's disease for many years are described.
Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies
TLDR
The identification of genomic biomarkers involved in drug response variability represents an important step in PD treatment, opening the prospective of more personalized therapies in order to identify, for each person, the better therapy in terms of efficacy and toxicity and to improve the PD patients’ quality of life.
Cabergoline : a review of its use in the treatment of Parkinson's disease.
TLDR
Data from two pharmacoeconomic analyses suggest that cabergoline may be a cost-effective treatment option versus levodopa in patients with early Parkinson's disease, and highlight the need for further evaluation of the drug in this indication.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Evaluating drug treatments for Parkinson's disease: how good are the trials?
TLDR
It is made the case that most trials of drug treatment for Parkinson's disease have crucial methodological faults—and provide little reliable evidence on differences between classes of drugs—and it is important to identify reliably the most effective drug therapy.
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
TLDR
Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001).
Is it time to abandon functional imaging in the study of neuroprotection?
  • P. Morrish
  • Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2002
Despite more than thirty years of use in clinical practice, and many major studies, we still do not know whether levodopa is toxic to dopaminergic neurones in Parkinson’s disease, or whether other
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
TLDR
Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.
Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD
TLDR
Short-term therapy with l-dopa and, to a lesser extent, pramipexole can modestly down-regulate striatal DAT in patients with early PD, suggesting caution in interpretation of longitudinal imaging studies employing DAT to assess disease progression and the efficacy of neuroprotective agents.
Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐hydroxydopamine
TLDR
It is shown that 1–10 μM of apomorphine protects rat pheochromocytoma (PC12) cells from the toxic effects of H2O2 and the neurotoxin 6‐hydroxydopamine and one may assume that apomorphines can exert a neuroprotective activity via its potent antioxidant properties.
Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
TLDR
The demonstrated toxicity of dopamine tends to support speculations that processes related to dopamine metabolism may play a role in the pathogenesis of Parkinson's disease, and suggest that 6‐OHDA cannot be considered a selective toxin for catecholaminergic neurons in vitro.
Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
TLDR
Pergolide may well be protective to dopaminergic neurons, largely because of its effects on presynaptic autoreceptors and on its induction of Cu/Zn superoxide dismutase.
...
1
2
...